Vikas Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vikas Jain has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
Hitesh Kumar
Apollo College of Pharmacy, Apollo Group of Institutions, Opp. Veterinary College, Anjora Durg, India
22 shared publicationsRupshee Jain
16 shared publicationsN. Vishal Gupta
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, Karnataka, India
7 shared publicationsSurajit Dey
Roseman University of Health Sciences, College of Pharmacy, Henderson, Nevada, USA
7 shared publicationsYirivinti Hayagreeva Dinakar
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India
7 shared publicationsPallavi Chand
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, India
6 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Elsevier in Medicine in Drug Discovery
- Vol. 29
Enhancing the therapeutic potential of plumbagin in breast cancer via advanced nanomedicine approaches
- 21 January 2026
- Published by Elsevier in Medicine in Drug Discovery
- Vol. 29
Open AccessEnhancing the therapeutic potential of plumbagin in breast cancer via advanced nanomedicine approaches
- 9 January 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (6) , 8619-8644
Enhancing Olaparib’s anti-cancer potential using nanostructured lipid carriers: formulation, evaluation, and in-vitro biological impact
Nanostructured lipid carriers (NLCs) containing olaparib (OLA) were designed and refined to enhance effectiveness against Triple Negative Breast Cancer (TNBC) in this study. The OLA-loaded NLC formulation was prepared by melt emulsification followed by ultrasonication. The formulation optimization was performed using a Box-Behnken design in DoE. The optimized NLCs consist of Gellucire® 50/13 as the solid lipid component, Labrafac® MC 60 as the liquid lipid, and Pluronic F 127 and PEG 400 as surfactants. Characterization of the optimized formulation revealed favourable physicochemical properties, including an average particle size of 126.0 ± 4.61 nm, a polydispersity index of 0.2 ± 0.012, a zeta potential of − 13.6 ± 1.21 mV, an entrapment efficiency of 88.5 ± 5.42%, and a drug loading of 14.8 ± 2.74%. Drug release kinetics indicated that the optimized NLC system provided sustained OLA delivery, with 84.49 ± 2.2% cumulative release over 72 h, contrasting significantly with unformulated OLA, which exhibited complete release within just 24 h. Compared with plain OLA, studies using MDA-MB-231 (TNBC) cell lines revealed that the optimized olaparib-loaded NLCs produced considerably greater efficacy (p < 0.05). These results suggest that nanostructured lipid carriers hold substantial promise for boosting the therapeutic efficacy of olaparib.
- 9 January 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (6) , 8619-8644
Enhancing Olaparib’s anti-cancer potential using nanostructured lipid carriers: formulation, evaluation, and in-vitro biological impact
Nanostructured lipid carriers (NLCs) containing olaparib (OLA) were designed and refined to enhance effectiveness against Triple Negative Breast Cancer (TNBC) in this study. The OLA-loaded NLC formulation was prepared by melt emulsification followed by ultrasonication. The formulation optimization was performed using a Box-Behnken design in DoE. The optimized NLCs consist of Gellucire® 50/13 as the solid lipid component, Labrafac® MC 60 as the liquid lipid, and Pluronic F 127 and PEG 400 as surfactants. Characterization of the optimized formulation revealed favourable physicochemical properties, including an average particle size of 126.0 ± 4.61 nm, a polydispersity index of 0.2 ± 0.012, a zeta potential of − 13.6 ± 1.21 mV, an entrapment efficiency of 88.5 ± 5.42%, and a drug loading of 14.8 ± 2.74%. Drug release kinetics indicated that the optimized NLC system provided sustained OLA delivery, with 84.49 ± 2.2% cumulative release over 72 h, contrasting significantly with unformulated OLA, which exhibited complete release within just 24 h. Compared with plain OLA, studies using MDA-MB-231 (TNBC) cell lines revealed that the optimized olaparib-loaded NLCs produced considerably greater efficacy (p < 0.05). These results suggest that nanostructured lipid carriers hold substantial promise for boosting the therapeutic efficacy of olaparib.
- 1 December 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 22 (10) , 1430-1440
Fabrication and Evaluation of Hyaluronic Acid-Coated Albumin Nanoparticles for Delivery of Gemcitabine
Background: Gemcitabine (Gem) is a well-known antineoplastic drug used to treat several solid tumors. The clinical application of Gem is hampered owing to its non-selectivity, short half-life, and drug resistance, which, therefore, necessitate the development of a suitable novel formulation that can selectively target cancer sites. Methods: In present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared by using the desolvation cross-linking method and coated with hyaluronic acid (HAGem- BSANPs) to target the CD44 receptor which overexpressed on several solid tumors. The developed NPs were characterized by particle size, zeta potential, Transmission Electron Microscopy (TEM), and Differential Scanning Calorimetry (DSC). Further anticancer activity of the developed formulation was evaluated against A549 and MCF-7 cells and explored mode of action studies. Results: The mean particle size and zeta potential of HA-Gem-BSANPs were observed as 144.7±5.67 nm and -45.72±3.24 mV, respectively. The TEM analysis also corroborated the particle size and shape, while thermal analysis (DSC) indicated that Gem was entrapped into NPs in an amorphous form. The nucleoside transport inhibition assay demonstrated that the NPs do not depend on transporters for cellular internalization, and hence, resistance development in cells is less expected against this formulation. HA-Gem-BSANPs exhibited higher cytotoxicity and apoptosis on both the tested cell lines. However, better cell-killing ability and mitochondrial membrane potential loss were observed against A549 due to CD44 expression. Conclusion: The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve Gem's therapeutic efficacy by selectively targeting the tumor site.
- 1 December 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 22 (10) , 1430-1440
Fabrication and Evaluation of Hyaluronic Acid-Coated Albumin Nanoparticles for Delivery of Gemcitabine
Background: Gemcitabine (Gem) is a well-known antineoplastic drug used to treat several solid tumors. The clinical application of Gem is hampered owing to its non-selectivity, short half-life, and drug resistance, which, therefore, necessitate the development of a suitable novel formulation that can selectively target cancer sites. Methods: In present work, Gem-loaded bovine serum albumin nanoparticles (Gem-BSANPs) have been prepared by using the desolvation cross-linking method and coated with hyaluronic acid (HAGem- BSANPs) to target the CD44 receptor which overexpressed on several solid tumors. The developed NPs were characterized by particle size, zeta potential, Transmission Electron Microscopy (TEM), and Differential Scanning Calorimetry (DSC). Further anticancer activity of the developed formulation was evaluated against A549 and MCF-7 cells and explored mode of action studies. Results: The mean particle size and zeta potential of HA-Gem-BSANPs were observed as 144.7±5.67 nm and -45.72±3.24 mV, respectively. The TEM analysis also corroborated the particle size and shape, while thermal analysis (DSC) indicated that Gem was entrapped into NPs in an amorphous form. The nucleoside transport inhibition assay demonstrated that the NPs do not depend on transporters for cellular internalization, and hence, resistance development in cells is less expected against this formulation. HA-Gem-BSANPs exhibited higher cytotoxicity and apoptosis on both the tested cell lines. However, better cell-killing ability and mitochondrial membrane potential loss were observed against A549 due to CD44 expression. Conclusion: The present work demonstrated that HA-Gem-BSANPs could be a potential strategy to improve Gem's therapeutic efficacy by selectively targeting the tumor site.
- 29 November 2025
- Published by Elsevier
- p. 199-233
Niosomes and ethosomes: Advances
- Open Access
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-11
POTENTIAL DRUG DELIVERY SYSTEMS AND DEVICE COMBINATION FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic Obstructive Pulmonary Disease (COPD) presents with chronic lung inflammation and poorly reversible airflow limitation, necessitating bronchodilators for management. The Global Initiative for COPD recommends combining Long-Acting Beta-Agonists (LABAs) and Long-Acting Antimuscarinic Agents (LAMAs) for most COPD patients. Developing fixed LAMA/lABA combinations is crucial. Adding an Inhaled Corticosteroid (ICS) to this combination may offer additional benefits, including preventing exacerbations. The GOLD report emphasizes diagnosis, prevention, exacerbation management, and addressing comorbidities. It advocates for holistic COPD management, integrating pharmacologic and non-pharmacologic approaches. Novel strategies like mono, dual, and triple therapies are recommended. The review highlights COPD's impact on COVID-19, comorbidities, and relevant patents concerning COPD and bronchodilators. The bronchodilator treatments may improve their efficacy in this critical aspect of COPD. Research shows that dual bronchodilation improves lung function and symptoms more consistently than mono-bronchodilation while potentially lowering the risk of exacerbations and disease deterioration and having a similar safety profile.
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 1-11
Open AccessPOTENTIAL DRUG DELIVERY SYSTEMS AND DEVICE COMBINATION FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic Obstructive Pulmonary Disease (COPD) presents with chronic lung inflammation and poorly reversible airflow limitation, necessitating bronchodilators for management. The Global Initiative for COPD recommends combining Long-Acting Beta-Agonists (LABAs) and Long-Acting Antimuscarinic Agents (LAMAs) for most COPD patients. Developing fixed LAMA/lABA combinations is crucial. Adding an Inhaled Corticosteroid (ICS) to this combination may offer additional benefits, including preventing exacerbations. The GOLD report emphasizes diagnosis, prevention, exacerbation management, and addressing comorbidities. It advocates for holistic COPD management, integrating pharmacologic and non-pharmacologic approaches. Novel strategies like mono, dual, and triple therapies are recommended. The review highlights COPD's impact on COVID-19, comorbidities, and relevant patents concerning COPD and bronchodilators. The bronchodilator treatments may improve their efficacy in this critical aspect of COPD. Research shows that dual bronchodilation improves lung function and symptoms more consistently than mono-bronchodilation while potentially lowering the risk of exacerbations and disease deterioration and having a similar safety profile.
- 24 January 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-22
A review of the current status of biological effects of plant-derived therapeutics in breast cancer
Phytochemicals are bioactive secondary plant metabolites found in high concentrations in fruits, grains, and vegetables. Recent studies provide evidence of usage of plant-based diets rich in phytochemicals and their corelation to reduction in cancer incidence. Several phytochemicals have demonstrated effectiveness as chemotherapeutic agents against various cancers, including breast cancer. Breast cancer (BC) is a major worldwide medical issue owing to its high incidence, especially in women. It is the most often detected malignancy and an important trigger of mortality in women. Various chemotherapeutics along with radiotherapy are being investigated as potential treatment options for breast cancer. However, multidrug resistance, toxicity to normal cells, and other adverse effects limit the usage of chemotherapeutics in breast cancer. Cancer treatment with dietary phytochemicals is a highly effective approach that is currently gaining widespread attention. This manuscript intends to describe the existing data on the anticancer effects of various phytochemicals, including their preclinical exploration against breast cancer. Phytochemicals are broadly categorized, with an explanation of their role in breast cancer prognosis through various signalling pathways, preclinical status, physicochemical property analysis using Data Warrior, and evidence on individual phototherapeutics.
- 24 January 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-22
A review of the current status of biological effects of plant-derived therapeutics in breast cancer
Phytochemicals are bioactive secondary plant metabolites found in high concentrations in fruits, grains, and vegetables. Recent studies provide evidence of usage of plant-based diets rich in phytochemicals and their corelation to reduction in cancer incidence. Several phytochemicals have demonstrated effectiveness as chemotherapeutic agents against various cancers, including breast cancer. Breast cancer (BC) is a major worldwide medical issue owing to its high incidence, especially in women. It is the most often detected malignancy and an important trigger of mortality in women. Various chemotherapeutics along with radiotherapy are being investigated as potential treatment options for breast cancer. However, multidrug resistance, toxicity to normal cells, and other adverse effects limit the usage of chemotherapeutics in breast cancer. Cancer treatment with dietary phytochemicals is a highly effective approach that is currently gaining widespread attention. This manuscript intends to describe the existing data on the anticancer effects of various phytochemicals, including their preclinical exploration against breast cancer. Phytochemicals are broadly categorized, with an explanation of their role in breast cancer prognosis through various signalling pathways, preclinical status, physicochemical property analysis using Data Warrior, and evidence on individual phototherapeutics.
- Open Access
- 7 November 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 190-200
DESIGN, SYNTHESIS, IN SILICO STUDIES, AND PHARMACOLOGICAL EVALUATION OF 5-ARYL-4-(CHLOROACETYLAMINO)-3-MERCAPTO-1,2,4-TRIAZOLE DERIVATIVES AS ANTICONVULSANT AGENTS
Objective: In this study, we reported the synthesis of a novel series of 5-aryl-4(chloroacetylamino)-3-mercapto-1, 2,4-triazoles. Methods: These compounds were synthesized to screen for anticonvulsant effects in a Maximal Electroshock Seizure (MES) model and a Subcutaneous Pentylenetetrazole (sc‐PTZ) seizure model in rats. Furthermore, molecular docking studies with gamma-aminobutyric acid and in silico ADME prediction were carried out to determine interactions of these compounds with Benzodiazepine (BZD) receptors and their similarity with standard drugs. The rotarod test was used to evaluate neurotoxicity. Results: 08 out of 40 compounds exhibited neurotoxicity at the maximum tested dose. Most of the compounds showed anti‐MES effects without any signs of neurological deficit. All the tested compounds significantly reduced seizures induced by PTZ compared to the control group. Carbamazepine and phenytoin were used as positive controls for anticonvulsant effects. Compounds 3d, 3h (a diphenylamine derivative of 5-aryl-4(chloroacetylamino)-3-mercapto-1,2,4-triazole), and 4a (a piperidinyl derivative of 5-aryl-4(chloroacetylamino)-3-mercapto-1,2,4-triazole) exhibited greater safety than phenytoin and carbamazepine in terms of neurotoxicity. The docking scores for the identified compounds 3d, 3h and 4a was 6.5133; 6.6558 and 5.6524, respectively. Nearly all the compounds (90%) demonstrated decreased locomotor activity. Conclusion: It is gratifying that the compounds with higher hydrophobicity showed better performance in the seizure models. Many triazole derivatives holding a suitable aryl or alkyl group gave a better anticonvulsant activity in their analogs.
- 7 November 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 190-200
Open AccessDESIGN, SYNTHESIS, IN SILICO STUDIES, AND PHARMACOLOGICAL EVALUATION OF 5-ARYL-4-(CHLOROACETYLAMINO)-3-MERCAPTO-1,2,4-TRIAZOLE DERIVATIVES AS ANTICONVULSANT AGENTS
Objective: In this study, we reported the synthesis of a novel series of 5-aryl-4(chloroacetylamino)-3-mercapto-1, 2,4-triazoles. Methods: These compounds were synthesized to screen for anticonvulsant effects in a Maximal Electroshock Seizure (MES) model and a Subcutaneous Pentylenetetrazole (sc‐PTZ) seizure model in rats. Furthermore, molecular docking studies with gamma-aminobutyric acid and in silico ADME prediction were carried out to determine interactions of these compounds with Benzodiazepine (BZD) receptors and their similarity with standard drugs. The rotarod test was used to evaluate neurotoxicity. Results: 08 out of 40 compounds exhibited neurotoxicity at the maximum tested dose. Most of the compounds showed anti‐MES effects without any signs of neurological deficit. All the tested compounds significantly reduced seizures induced by PTZ compared to the control group. Carbamazepine and phenytoin were used as positive controls for anticonvulsant effects. Compounds 3d, 3h (a diphenylamine derivative of 5-aryl-4(chloroacetylamino)-3-mercapto-1,2,4-triazole), and 4a (a piperidinyl derivative of 5-aryl-4(chloroacetylamino)-3-mercapto-1,2,4-triazole) exhibited greater safety than phenytoin and carbamazepine in terms of neurotoxicity. The docking scores for the identified compounds 3d, 3h and 4a was 6.5133; 6.6558 and 5.6524, respectively. Nearly all the compounds (90%) demonstrated decreased locomotor activity. Conclusion: It is gratifying that the compounds with higher hydrophobicity showed better performance in the seizure models. Many triazole derivatives holding a suitable aryl or alkyl group gave a better anticonvulsant activity in their analogs.
- 23 October 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (3) , 2387-2406
Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells
Breast cancer is a common and deadly malignancy that affects women globally, and breast cancer stem cells (BCSCs) play an important role in tumorigenesis, development, metastasis, and recurrence. Traditional therapies often fail to eliminate BCSCs, leading to treatment resistance and relapse. This review explores the therapeutic strategies which are designed to target BCSCs, including inhibition of key signaling pathway and targeting receptor. This paper also explores the approaches to targeting BCSCs including chemotherapy, phytomedicines, and nanotechnology. Nanotechnology has gained a lot of importance in cancer therapy because of its ability to deliver therapeutic agents with more precision and minimal side effects. Various chemotherapeutic drugs, siRNAs, or gene editing tools are delivered efficiently with the use of nanocarriers which target pathways, receptors, and proteins associated with BCSCs. Over the past few years, stimuli-responsive and receptor-targeted nanocarriers have been explored for better therapeutic effects. In recent times, strategies such as chimeric antigen receptor (CAR) T-cell therapy, ablation therapy, and cell-free therapies are explored for targeting these stem cells. This review provides a recent developmental overview of strategies to attack BCSCs from conventional chemotherapeutic agents to nanotechnological platforms such as polymeric, lipidic, and metal-based nanoparticles and advanced technologies like CAR T cell therapies. Graphical Abstract
- 23 October 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (3) , 2387-2406
Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells
Breast cancer is a common and deadly malignancy that affects women globally, and breast cancer stem cells (BCSCs) play an important role in tumorigenesis, development, metastasis, and recurrence. Traditional therapies often fail to eliminate BCSCs, leading to treatment resistance and relapse. This review explores the therapeutic strategies which are designed to target BCSCs, including inhibition of key signaling pathway and targeting receptor. This paper also explores the approaches to targeting BCSCs including chemotherapy, phytomedicines, and nanotechnology. Nanotechnology has gained a lot of importance in cancer therapy because of its ability to deliver therapeutic agents with more precision and minimal side effects. Various chemotherapeutic drugs, siRNAs, or gene editing tools are delivered efficiently with the use of nanocarriers which target pathways, receptors, and proteins associated with BCSCs. Over the past few years, stimuli-responsive and receptor-targeted nanocarriers have been explored for better therapeutic effects. In recent times, strategies such as chimeric antigen receptor (CAR) T-cell therapy, ablation therapy, and cell-free therapies are explored for targeting these stem cells. This review provides a recent developmental overview of strategies to attack BCSCs from conventional chemotherapeutic agents to nanotechnological platforms such as polymeric, lipidic, and metal-based nanoparticles and advanced technologies like CAR T cell therapies. Graphical Abstract
- 25 September 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (11) , 871-891
Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
Breast cancer is the leading cause of cancer-related deaths among women globally. The difficulties with anticancer medications, such as ineffective targeting, larger doses, toxicity to healthy cells and side effects, have prompted attention to alternate approaches to address these difficulties. RNA interference by small interfering RNA (siRNA) is one such tactic. When compared with chemotherapy, siRNA has several advantages, including the ability to quickly modify and suppress the expression of the target gene and display superior efficacy and safety. However, there are known challenges and hurdles that limits their clinical translation. Decomposition by endonucleases, renal clearance, hydrophilicity, negative surface charge, short half-life and off-target effects of naked siRNA are obstacles that hinder the desired biological activity of naked siRNA. Nanoparticulate systems such as polymeric, lipid, lipid-polymeric, metallic, mesoporous silica nanoparticles and several other nanocarriers were used for effective delivery of siRNA and to knock down genes involved in breast cancer and triple-negative breast cancer. The focus of this review is to provide a comprehensive picture of various strategies utilized for delivering siRNA, such as combinatorial delivery, development of modified nanoparticles, smart nanocarriers and nanocarriers that target angiogenesis, cancer stem cells and metastasis of breast cancer.
- 25 September 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (11) , 871-891
Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
Breast cancer is the leading cause of cancer-related deaths among women globally. The difficulties with anticancer medications, such as ineffective targeting, larger doses, toxicity to healthy cells and side effects, have prompted attention to alternate approaches to address these difficulties. RNA interference by small interfering RNA (siRNA) is one such tactic. When compared with chemotherapy, siRNA has several advantages, including the ability to quickly modify and suppress the expression of the target gene and display superior efficacy and safety. However, there are known challenges and hurdles that limits their clinical translation. Decomposition by endonucleases, renal clearance, hydrophilicity, negative surface charge, short half-life and off-target effects of naked siRNA are obstacles that hinder the desired biological activity of naked siRNA. Nanoparticulate systems such as polymeric, lipid, lipid-polymeric, metallic, mesoporous silica nanoparticles and several other nanocarriers were used for effective delivery of siRNA and to knock down genes involved in breast cancer and triple-negative breast cancer. The focus of this review is to provide a comprehensive picture of various strategies utilized for delivering siRNA, such as combinatorial delivery, development of modified nanoparticles, smart nanocarriers and nanocarriers that target angiogenesis, cancer stem cells and metastasis of breast cancer.
- Open Access
- 7 September 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 119-132
FORMULATION AND EVALUATION OF ETODOLAC AND TRIAMCINOLONE ACETONIDE LOADED NANO LIPID CARRIER GELS FOR THE THERAPEUTIC MANAGEMENT OF OSTEOARTHRITIS PAIN THROUGH TOPICAL ADMINISTRATION: A COMPARATIVE STUDY
Objective: The present study aims to prepare carbopol-based hydrogels loaded with Etodolac (EDT), and Triamcinolone Acetonide (TCA) incorporated Nanolipid Carriers (NLCs) (EDTg and TCAg) to compare the efficacy and potency of both drugs for Osteoarthritis (OA) pain management. Methods: EDT-NLCs and TCA-NLCs were prepared with the help of the solvent evaporation method after screening the lipids, and the NLCs were optimized. The optimized NLC formulations EDT-NLC and TCA-NLCs were examined for particle size, PDI, zeta otential, Differential Scanning Calorimetry (DSC), Powder X-ray Diffraction (PXRD), Transmission Electron Mcroscopy (TEM) and in vitro release. The prepared EDTg and TCAg have been evaluated with in vitro drug release, ex-vivo skin permeation, and in vivo pharmacokinetic and pharmacodynamic parameters. Results: DSC and PXRD graphs showed a decrease in melting point and the amorphous form of the optimized NLC formulation. Different evaluation tests revealed that the EDT-NLCs and TCA-NLCshad particle size of 161±0.0021 nm and 167.4±0.0010 nm, PDI of 0.148±0.023 and 0.130±0.01, and zeta potential of-14 mV and-15 mV respectively, indicating their distinct nature. In vitro drug release study, ETDg showed 89.84±1.71 % release, while TCAg released 94.75±1.79 % after 24 h of application. ETDg permeated 86.5±1.68% of EDT-NLCs through the dorsal skin, compared to TCA-NLCs 76.5±1.13 %in an ex vivo skin permeation investigation. A pharmacokinetic study identified 76.3±1.98 % of EDT-NLCs and 63.25±2.003 of TCA-NLCs in drug plasma. Pharmacodynamic characteristics like X-ray analysis, Immuno Histochemistry (IHC), and histopathology indicated that EDTg and TCAg managed OA pain. All evaluation tests carried out in this research showed that formulated hydrogels could manage OA. Conclusion: The results suggested in this research prove EDTg to have a higher potentiality than TCAg for the management of OA pain
- 7 September 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 119-132
Open AccessFORMULATION AND EVALUATION OF ETODOLAC AND TRIAMCINOLONE ACETONIDE LOADED NANO LIPID CARRIER GELS FOR THE THERAPEUTIC MANAGEMENT OF OSTEOARTHRITIS PAIN THROUGH TOPICAL ADMINISTRATION: A COMPARATIVE STUDY
Objective: The present study aims to prepare carbopol-based hydrogels loaded with Etodolac (EDT), and Triamcinolone Acetonide (TCA) incorporated Nanolipid Carriers (NLCs) (EDTg and TCAg) to compare the efficacy and potency of both drugs for Osteoarthritis (OA) pain management. Methods: EDT-NLCs and TCA-NLCs were prepared with the help of the solvent evaporation method after screening the lipids, and the NLCs were optimized. The optimized NLC formulations EDT-NLC and TCA-NLCs were examined for particle size, PDI, zeta otential, Differential Scanning Calorimetry (DSC), Powder X-ray Diffraction (PXRD), Transmission Electron Mcroscopy (TEM) and in vitro release. The prepared EDTg and TCAg have been evaluated with in vitro drug release, ex-vivo skin permeation, and in vivo pharmacokinetic and pharmacodynamic parameters. Results: DSC and PXRD graphs showed a decrease in melting point and the amorphous form of the optimized NLC formulation. Different evaluation tests revealed that the EDT-NLCs and TCA-NLCshad particle size of 161±0.0021 nm and 167.4±0.0010 nm, PDI of 0.148±0.023 and 0.130±0.01, and zeta potential of-14 mV and-15 mV respectively, indicating their distinct nature. In vitro drug release study, ETDg showed 89.84±1.71 % release, while TCAg released 94.75±1.79 % after 24 h of application. ETDg permeated 86.5±1.68% of EDT-NLCs through the dorsal skin, compared to TCA-NLCs 76.5±1.13 %in an ex vivo skin permeation investigation. A pharmacokinetic study identified 76.3±1.98 % of EDT-NLCs and 63.25±2.003 of TCA-NLCs in drug plasma. Pharmacodynamic characteristics like X-ray analysis, Immuno Histochemistry (IHC), and histopathology indicated that EDTg and TCAg managed OA pain. All evaluation tests carried out in this research showed that formulated hydrogels could manage OA. Conclusion: The results suggested in this research prove EDTg to have a higher potentiality than TCAg for the management of OA pain